We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Closing Down mTOR Signaling Prevents Prostate Tumor Metastasis

By LabMedica International staff writers
Posted on 12 Mar 2012
An experimental drug the blocks the activity of the molecular pathway moderated by the mTOR (mammalian target of rapamycin) kinase enzyme prevented prostate tumor metastasis in a mouse model of the disease.

mTOR is a master regulator of protein synthesis that under ordinary conditions induces cells to grow and divide. More...
In situations of severe nutrient deprivation, mTOR closes down protein synthesis so that the cell can conserve energy. However, in cancer cells the mTOR pathway misfires and signals tumor cells to grow, divide, undergo metastasis, and invade new, healthy tissues.

Investigators at the University of California, San Francisco (USA) sought to identify the proteins controlled by mTOR signaling in order to understand better how it could be targeted by drugs that would block this activity.

The investigators reported in the February 22, 2012, online edition of the journal Nature that by using an advanced ribosome profiling technique, they had uncovered specialized translation of the prostate cancer genome by oncogenic mTOR signaling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metabolism, and invasion. They extended these findings by functionally characterizing a class of translationally controlled proinvasion messenger RNAs that directed prostate cancer invasion and metastasis downstream of oncogenic mTOR signaling. In addition, they developed a clinically relevant ATP site inhibitor of mTOR, INK128, which reprogrammed this gene expression signature with therapeutic benefit for prostate cancer metastasis.

"We are now discovering that during tumor formation mTOR leads to metastasis by altering the synthesis of a specific group of proteins that make the cancer cells move and invade normal organs,” said senior author Dr. Davide Ruggero, associate professor of urology at the University of California, San Francisco. "Many human cancers show hyperactivation of this pathway. Until now, we have not known how hyperactive mTOR perturbs the synthesis of certain proteins leading to fatal cancer. Deregulations in protein synthesis are now becoming a hallmark of cancer, and we are very excited by the opportunity to target the aberrant protein synthesis apparatus in many cancers."

Related Links:
University of California, San Francisco


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Immunofluorescence Analyzer
IFA System
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.